Duchenne muscular dystrophy (DMD) is the most common inherited muscular disease and is characterized by progressive muscle wasting. DMD is caused by mutations in the dystrophin gene on Xp21.2. One-third of DMD cases are complicated by mental retardation, but the pathogenesis of this is unknown. We have identified an intrachromosomal inversion, inv(X)(p21.2;q28) in a DMD patient with mental retardation. We hypothesized that a gene responsible for the mental retardation in this patient would be disrupted by the inversion. We localized the inversion break point by analysis of dystrophin complementary DNA (cDNA) and fluorescence in situ hybridization. We used 5 0 and 3 0 rapid amplification of cDNA ends to extend the known transcripts, and reverse transcription-PCR to analyze tissue-specific expression. The patient's dystrophin cDNA was separated into two fragments between exons 18 and 19. Exon 19 was dislocated to the long arm of the X-chromosome. We identified a novel 109-bp sequence transcribed upstream of exon 19, and a 576-bp sequence including a poly(A) tract transcribed downstream of exon 18. Combining the two novel sequences, we identified a novel gene, named KUCG1, which comprises three exons spanning 50 kb on Xq28. The 685-bp transcript has no open-reading frame, classifying it as a long non-coding RNA. KUCG1 mRNA was identified in brain. We cloned a novel long non-coding gene from a chromosomal break point. It was supposed that this gene may have a role in causing mental retardation in the index case.
INTRODUCTION
Duchenne muscular dystrophy (DMD) is the most common inherited muscle disease affecting approximately one in 3500 males and is characterized by progressive muscle wasting during childhood. DMD shows muscle dystrophin deficiency because of mutations in the dystrophin gene that comprises 79 exons spanning 42500 kb on chromosome Xp21.2. 1 Mutations in the dystrophin gene range from single-nucleotide changes to chromosomal abnormalities (http:// www.dmd.nl/). 2 Deletions encompassing one or more exons of the dystrophin gene are the most common cause of DMD and account for B60% of mutations. 3 Disastrous mutations such as an out-of-frame deletion or nonsense mutation result in severe DMD. 4 DMD is complicated by mental retardation in one-third of patients. 5 Many studies have been conducted to elucidate the pathogenic mechanism of this complicating mental retardation. There are now several reports describing that mutations at the 3 0 end of the dystrophin gene are related to complication with mental retardation. 6, 7 In a small portion of DMD patients, gross chromosomal rearrangements have been reported as the cause of dystrophin deficiency. In fact, a huge intrachromosomal deletion showing contiguous gene deletion syndrome was used to clone the dystrophin gene. 8 Intrachromosomal inversions have been identified in DMD. 9, 10 X-autosome translocations involving the dystrophin gene have also been identified in a limited number of DMD patients. 11, 12 Disease-associated chromosomal rearrangements have been frequently used as a starting point in the elucidation of congenital disorders. Disrupted X-chromosomal genes are even more promising in this respect as they often represent knockouts. 10, 13 In one DMD patient with complicating mental retardation, for example, an intrachromosomal inversion led to the identification of a Ras-like GTPase gene that causes mental retardation. 9 In addition, 420 genes have been identified by studying balanced X-chromosome rearrangements. 14 The genes for X-linked mental retardation are largely unknown. [14] [15] [16] In a series of 442 Japanese mutations in the dystrophin gene, we have described a karyotype of 46,Y,inv (X)(p21.2;q28) to be the cause of one case of DMD. 2 This case was complicated with moderate mental retardation and it is thought very likely that the inversion disrupts one of the 440 genes responsible for mental retardation at Xq28. 17 A diverse population of non-protein-coding RNAs has been reported in the human genome. 18, 19 Long non-coding RNAs (lncRNAs), defined as greater than 200 nucleotides (nt) in length, 20 have a wide range of functions, including the regulation of transcription, RNA editing and organelle biogenesis. 19, 21, 22 It has been suggested that a subset of lncRNAs could contribute to neurological disorders when they become dysregulated. 23 In this study, we characterized an intrachromosomal inversion inv(X)(p21.2;q28). We identified a novel long non-coding gene named KUCG1 at the break point on Xq28. As this gene was expressed in the brain, we propose that disruption of the KUCG1 gene may have a role in causing the mental retardation in the index case.
MATERIALS AND METHODS Patient
The index patient is a 3-year-old Japanese boy. He is the first child of healthy, non-consanguineous, Japanese parents. Family history was unremarkable. When he was born at term, blood sampling was performed because of birth asphyxia. Unexpectedly, his serum creatine kinase level was highly elevated (25 510 IU l À1 ; normal:o270 IU l À1 ). He walked unassisted at the age of 15 months. As the high creatine kinase level persisted, a muscle biopsy was conducted at the age of 2 years to examine dystrophin expression. Dystrophin staining using monoclonal antibodies to three different domains revealed no reactive material in his skeletal muscle, confirming the diagnosis of DMD. He was referred to Kobe University Hospital for a genetic diagnosis (KUCG481). At the age of 3 years, his serum creatine kinase was 21 776 IU l À1 . His growth parameters were normal but he displayed moderate mental retardation (developmental quotient: 40). Brain magnetic resonance imaging findings were normal. His karyotype has been described in our previous report as 46,Y, inv(X)(p21.2;q28). 2 The inversion was inherited through his mother (data not shown). The protocol for the following study was approved by the ethical committee of Kobe University School of Medicine.
Dystrophin mRNA analysis
RNA was isolated from biopsied skeletal muscle and analyzed by reverse transcription-PCR as described previously. 24, 25 The full-length dystrophin complementary DNA (cDNA) was amplified as 10 separate fragments. 26 To identify the break point within the dystrophin cDNA, fragments encompassing exons 18 and 19 were amplified using different sets of primers. The ends of two separate dystrophin cDNAs were confirmed by PCR amplification using newly designed primers; a reverse primer on exon 18 and a forward primer on exon 19, respectively (Table 1) .
PCR amplification
PCR amplification was performed in a total volume of 20 ml, containing 2 ml of cDNA, 2 ml of 10 Â ExTaq buffer (Takara Bio, Inc., Shiga, Japan), 0.5 U of ExTaq polymerase (Takara Bio, Inc.), 500 nM of each primer and 250 mM deoxyribonucleotide triphosphates (Takara Bio, Inc.). Thirty-five cycles of amplification were performed on a Mastercycler Gradient PCR machine (Eppendorf, Hamburg, Germany) using the following conditions: initial denaturation at 94 1C for 5 min, subsequent denaturation at 94 1C for 0.5 min, annealing at 59 1C for 0.5 min and extension at 72 1C for 1 min. The conditions were sometimes slightly modified for optimization. For nested or semi-nested PCR, 2 ml of the first reaction mixture was used as the template for the second amplification. The amplified PCR products were electrophoresed on 2% agarose gels with a low-molecular weight DNA standard (fX174-Hae III digest; Takara Bio, Inc.) and stained with ethidium bromide.
Fluorescence in situ hybridization
Fluorescence in situ hybridization was conducted on metaphase spreads from the patients' lymphocytes with digoxigenin-labeled PCR product containing exons 18 or 19 of the dystrophin gene in combination with DXZ1 spectrum green probe for the X centromere (Vysis, Inc., Downers Grove, IL, USA). The exon 18 and 19 probes were detected by immunocytochemistry. This assay was carried out commercially by Mitsubishi Chemical Medience Co. (Tokyo, Japan).
5
0 -Rapid amplification of cDNA ends 5 0 -Rapid amplification of cDNA ends (RACE) was performed to obtain the 5 0 -end of the transcript using the 5 0 -RACE System Version 2 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions, with primers specific for the dystrophin mRNA (Table 1) . Total RNA isolated from the patient's skeletal muscle was reverse transcribed using a gene-specific primer (c24r) and SuperScript II, a derivative of Moloney Murine Leukemia Virus Reverse Transcriptase (Invitrogen). PCR amplification was then performed using Taq DNA polymerase (Takara Bio, Inc.), a nested gene-specific primer (c21r), and a deoxyinosine-containing anchor primer provided with the system. A nested amplification using an inner gene-specific primer (c20r) and the anchor primer from the provider was also performed.
3
0 -Rapid amplification of cDNA ends 3 0 -RACE was performed to obtain the 3 0 -end of the transcript using the 3 0 -RACE System Version 2 (Invitrogen) with primers specific for the dystrophin mRNA (Table 1) . First-strand cDNA synthesis was initiated at the poly(A) tail of mRNA using the adapter primer from the provider. After first-strand cDNA synthesis, the original mRNA template was destroyed with RNase H. Amplification was performed using a gene-specific primer (c16f) and a universal amplification primer from the provider that targets the cDNA complementary to the 3 0 -end of the mRNA. A nested amplification using an inner gene-specific primer (c18f) and the anchor primer from the provider was also performed. 
DNA sequencing
PCR-amplified bands were excised from the gel with a sharp razor blade, pooled and purified using a QIAGEN gel extraction kit (QIAGEN, Inc., Hilden, Germany) according to the manufacturer's instructions. Purified products were sequenced either directly or after subcloning into the pT7 Blue T-vector (Novagen, San Diego, CA, USA). DNA sequencing was performed using a BigDye 1.1 Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA) in a Mastercycler Gradient (Eppendorf). The DNA sequences were determined using an automated DNA sequencer (ABI 310; Applied Biosystems).
mRNA expression of KUCG1
The expression of the KUCG1 transcript was examined by reverse transcription-PCR. Human total RNA from 21 tissues (adrenal gland, bone marrow, brain, colon, fetal brain, fetal liver, heart, kidney, liver, lung, lymphocytes, placenta, prostate, salivary gland, skeletal muscle, spinal cord, testis, thymus, thyroid gland, trachea and uterus) was obtained from a human total RNA Master Panel II (Clontech Laboratories, Inc., Mountain View, CA, USA). cDNA was synthesized as described previously 27 from 2.5 mg of each total RNA. The KUCG1 transcript spanning exon 2 to exon 3 was amplified by seminested PCR using primers Bf and Cr2, then Bf and Cr1 (Table 1) , yielding a 314-bp fragment.
To check the integrity and concentration of the cDNA, the glyceraldehyde-3-phosphate dehydrogenase gene was also reverse transcription-PCR amplified, as described previously. 28 Database searches and multiple sequence alignments Homology searching was performed using the National Center for Biotechnology Information BLAST program (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The cloned 658-bp sequence was searched using NONCODE v3.0. 29 The core promoter of the KUCG1 gene was analyzed using Genety X (Ver. 8.2.0) (GENETYX corporation, Tokyo, Japan).
RESULTS
We performed a molecular characterization of an intrachromosomal inversion in a DMD patient, inv(X)(p21.2;q28). We were able to amplify all 79 dystrophin exon-encompassing regions from the patient's genome (data not shown), indicating that the overall structure of the gene was intact. We examined the full-length dystrophin cDNA as 10 separate fragments. All the cDNA fragments could be obtained by PCR except one that covered exons 17 to 25 (data not shown). This suggested that the dystrophin cDNA was separated into two fragments; one from exons 1 to 18 and the other from exons 19 to 79 (data not shown). We used fluorescence in situ hybridization to confirm this. As expected, an exon 19 probe hybridized to the long arm of the X-chromosome, while an exon 18 probe hybridized to the short arm ( Figure 1 ). We concluded that the exon 19 dislocation from the short arm to the long arm was the cause of DMD.
We were surprised the distal dystrophin cDNA (exons 19 to 78) could be PCR amplified, because this indicated that it formed a new fusion gene after dislocation. We, therefore, examined the full-length transcript using skeletal muscle RNA from the patient (Figure 2 ). We obtained a 5 0 -RACE product from exon 20, which contained 109 bp between the adapter and dystrophin exon 19 sequence (Figure 2 ). Homology searching of the identified sequence revealed that, although it did not match any known gene, it was identical to a portion of Xq28 (GenBank ID: NW001842413.1). The first nucleotide of the cloned sequence was 89,813 bp downstream from the melanoma antigen family A, 9 (MAGEA9) gene (Figure 3) . Examination of the genomic sequence 3 0 of the cloned 109-bp sequence revealed a GT dinucleotide, a splice donor consensus sequence (Figure 2) . Although an AG dinucleotide-a consensus splice acceptor sequence was not present at the 5 0 -end, we did identify a TATA-box 5 0 -(ATATATAA CAATTTA)-3 0 , GC-box 5 0 -(TAAGGGCATACCCT)-3 0 and CCAATbox 5 0 -(CCTAGCCAATAG)-3 0 at 168, 266 and 372 bp upstream of the cloned sequence, respectively (Figure 2 ). Additionally, a cap signal sequence (TCAGCAAC) was present 24 bp upstream. These characteristics indicated that the cloned sequence was the first exon of an unknown gene that is transcribed in the centromere-to-telomere direction. We concluded that, in the patient, the first exon of the To identify the rest of the novel gene, we conducted 3 0 -RACE using a primer in exon 16, and obtained one clear product (Figure 4) . Sequencing of the amplified product revealed a 583-bp sequence inserted between dystrophin exon 18 and the adapter sequence ( Figure 4 ). Homology searching revealed that this sequence, apart from the last seven 'A' nt, matched two separate regions of Xq28. The first 123 bp that were continuous with the 3 0 -end of exon 18 completely matched nt 148986563-148986685 and the last 453 bp matched nt 149008147-149008599 (NC 00023.10). The last nucleotide was located 4448 bp upstream of the melanoma antigen family A, 8 (MAGEA8) gene (Figure 3) . Examination of the genomic sequences flanking the first 123 bp revealed consensus splice donor and acceptor sites at the 3 0 and 5 0 ends, respectively, indicating that it is an internal exon of an unknown gene. The last 453 bp had an AG dinucleotide immediately upstream but no GT dinucleotide downstream. Instead, a consensus polyadenylation signal (AATAAA) was identified 14 bp upstream of the 3 0 -end ( Figure 4) . 30 Considering the stretch of seven 'A's as part of a poly(A) tail, we concluded that the 453 bp sequence was the last exon of the unknown gene. The dystrophin promoter would produce a chimeric transcript comprising dystrophin exons 1-18 and two novel exons at the 3 0 -end. Combining the results of 5 0 and 3 0 -RACE, we had cloned a 685-bplong transcript, the sequence of which we deposited in GenBank under the accession number JX283354. Homology searching did not reveal any transcript with significant similarity. The transcript had no significant open-reading frame, but because of its mRNA-like structure and length of 4200 bp, we concluded that it was a novel lncRNA. We named it KUCG1. KUCG1 spans nearly 50 kb on Xq28 and is located 9.0 kb downstream of MAGEA9 and 4.4 kb upstream of MAGEA8 (Figure 3 ). It has three exons separated by two introns (32 kb and 20 kb long, respectively) . The site of recombination of the intrachromosomal inversion inv(X)(p21.2;q28) was intron 1. The inversion caused a head-to-tail fusion of KUCG1 and dystrophin at the recombination sites. We searched for homologous lncRNAs using NONCODE v3.0, 29 but did not identify any significant matches. This indicated that KUCG1 is a novel lncRNA. It was found that exon 3 of KUCG1 overlaps with the antisense transcript RP5-869M20.2, an lncRNA of unknown function (Figure 3) .
We next examined the tissue-specific expression of KUCG1 in humans. We amplified a fragment comprising exons 2 to 3 by reverse transcription-PCR of total RNA from 21 human tissues. The expected size product was obtained by semi-nested PCR from four tissues (lung, thyroid gland, brain and placenta), whereas no product was obtained from the other 17 tissues ( Figure 5 ). Considering the brain expression of KUCG1, we consider that its disruption may be responsible for the moderate mental retardation in the index case.
DISCUSSION
In this report, we describe molecular characterization of an inverted X (p21.2;q28) chromosome in a patient with DMD and mental retardation. The inversion disrupted both the dystrophin gene, presumed to be the cause of the DMD, and a novel lncRNA, KUCG1, which may be the cause of the mental retardation. This is the third intrachromosomal inversion to be molecularly clarified in DMD, 9, 10 but the first to disrupt unknown gene directly.
The KUCG1 mRNA was detected in 4 out of 21 tissues: lung, thyroid gland, brain and placenta ( Figure 5 ), indicating tissue-specific gene regulation despite the presence of three common consensus sequences in the promoter. The tissue-restricted expression and low expression level (semi-nested PCR was required to detect a product) could explain why this lncRNA has not been previously detected among the thousands of ncRNAs identified by high-throughput sequencing. 31 What is the function of the KUCG1 gene? As it undergoes splicing, is 4200 nt long, and contains features such as a poly(A) signal/tail, KUCG1 can be considered an mRNA-like ncRNA. 32, 33 lncRNAs have been shown to have key roles in imprinting control, immune responses and human disease; 20 for instance, an ncRNA cloned from a chromosomal inversion was recently demonstrated to cause autosomal dominant hypertension and brachydactyly (OMIM 112410). 34 In the central nervous system, the increasing variety of ncRNAs shown to be expressed has suggested a strong connection between ncRNAs and the complexity of the system. 35 Hundreds of lncRNAs have been shown to localize to specific neuroanatomical regions, cell types or subcellular compartments within the brain 36 and a subset of lncRNAs is likely to contribute to neurological disorders. 23 For instance, the levels of the linc-MD1 lncRNA are strongly reduced in DMD, 37 indicating a role for this lncRNA in the disease pathology of DMD.
The mechanism of action of lncRNAs is thought to involve direct binding to target sites on proteins and RNAs. 33, 37 It is interesting that exon 3 of KUCG1 overlaps with the antisense transcript RP5-869M20.2, an lncRNA of unknown function. It is possible that transcripts from KUCG1 and RP5-869M20.2 form a doublestranded RNA that has a particular physiological role.
As KUCG1 is expressed in the brain, we suspect that its disruption is responsible for the moderate mental retardation in the index case. Although 440 genes responsible for X-linked mental retardation have been annotated to Xq28, 17 the gene(s) responsible for many cases of X-linked mental retardation remain unidentified. 14 To test whether KUCG1 is responsible for other cases of X-linked mental retardation, we sequenced KUCG1 in ten Japanese families with X-linked mental retardation for which no responsible gene mutation has been identified. No mutations were identified (data not shown). Although we have not provided direct evidence linking mental retardation to mutation of KUCG1, further studies of its function, and mutation analysis in other X-linked mental retardation families, is warranted.
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